U.S. RESEARCH ROUNDUP-Atara Biotherapeutics, Enphase Energy, Zynerba Pharmaceuticals

Green Plains Partners LP

16/09/2019 08:31

Sept 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Atara Biotherapeutics, Enphase Energy and Zynerba
Pharmaceuticals, on Monday. 
    
  HIGHLIGHTS
     * Atara Biotherapeutics Inc  ATRA.O : Jefferies cuts to hold from buy
     * Enphase Energy  ENPH.O : JP Morgan initiates coverage with overweight rating 
     * Zynerba Pharmaceuticals Inc  ZYNE.O : Jefferies raises target price to $11 from $5.50
 
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.

     * Apple Inc  AAPL.O : Evercore ISI raises price target to $247 from $238
     * Atara Biotherapeutics Inc  ATRA.O : Jefferies cuts to hold from buy
     * Atara Biotherapeutics Inc  ATRA.O : Jefferies cuts price target to $15 from $32
     * Enphase Energy  ENPH.O : JP Morgan initiates coverage with overweight rating 
     * Enphase Energy  ENPH.O : JP Morgan initiates coverage with $32 Dec 2020 price target
     * Exxon Mobil  XOM.N : Berenberg cuts price target to $73 from $76
     * Fedex Corp  FDX.N : JP Morgan cuts Dec 2020 target price to $168 from $172
     * Green Plains Partners LP  GPP.O : RBC cuts price target to $15 from $18
     * L3Harris Technologies Inc  LHX.N : Jefferies raises price target to $250 from $235
     * MPLX LP  MPLX.N : Citigroup cuts price target to $32 from $40
     * Southern Co  SO.N : Evercore ISI raises price target to $55.25 from $53.50
     * Square Inc  SQ.N : Evercore ISI cuts price target to $50 from $64
     * Viacom Inc  VIAB.O : Citigroup cuts price target to $29 from $31
     * Zynerba Pharmaceuticals Inc  ZYNE.O : Jefferies raises target price to $11 from $5.50
 

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))